Compare DRCT & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRCT | AZTR |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | United States | United States |
| Employees | 73 | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8M | 1.9M |
| IPO Year | 2021 | 2023 |
| Metric | DRCT | AZTR |
|---|---|---|
| Price | $0.57 | $0.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $8.00 | $4.00 |
| AVG Volume (30 Days) | 79.8K | ★ 21.5M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.06 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $34,694,000.00 | N/A |
| Revenue This Year | $58.20 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.04 | $0.10 |
| 52 Week High | $6.04 | $1.40 |
| Indicator | DRCT | AZTR |
|---|---|---|
| Relative Strength Index (RSI) | 29.44 | 51.35 |
| Support Level | $0.34 | $0.22 |
| Resistance Level | $0.61 | $0.23 |
| Average True Range (ATR) | 0.09 | 0.03 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 12.54 | 15.05 |
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.